July 15, 2020 | Reading Time: 2 minutes
Early this morning we announced an initiative to deliver and enhance a minimally invasive circulating tumor DNA (ctDNA) test to cancer patients across Canada in response to COVID-19. Thousands have been adversely affected since the pandemic forced health systems to delay or cancel surgeries including tissue biopsies.
Supported by the Digital Technology Supercluster, Project ACTT – Access to Cancer Testing & Treatment in Response to COVID-19 makes testing immediately available to 2,000 patients with lung, breast, or colorectal cancer in Canada. We are honoured to lead this project in partnership with Queen’s University, AstraZeneca Canada, the Eastern Ontario Regional Laboratory Association, Genolife, Semaphore Solutions, emtelligent, Xtract AI, Novateur, and Illumina.
Working with this impressive roster, we will also enhance the ctDNA solution to detect a broader range of cancer types, increasing the potential reach from 40,000 to 70,000 cancer patients each year in Canada alone. Further, the project will generate the data required to determine if this testing can be delivered under provincial health coverage — making it possible to conduct tests in-house at Canadian hospitals and labs, increasing availability in remote and rural areas, and future-proofing against COVID-19 and other pandemics.
Read more about Project ACTT in today’s press release.
Learn more about how to get tested
Today also marks another important milestone for our company.
Over the past year, we have grown our commercial team, welcomed new customers and collaborators, and are on the path to fundamentally change how patients and oncologists gain information about cancer treatment selection. During this time, we have also heard from prospective partners, oncologist groups, and patients that our company name did not fully communicate our expertise beyond genomics. We thus embarked on a journey to identify a corporate name reflective of our work today and our strategic vision for the future.
As of today, our company is now Canexia Health.
Canexia Health represents our deep focus on cancer patients, our commitment to exacting knowledge, and the community nexus we are building with partners to make precision oncology affordable and accessible. What has changed? Our name, logo, and visual assets including our newly refreshed website. Our mission remains, and there is no impact on how we operate.
More to come in the coming weeks on this exciting new chapter. In the meantime, visit us at www.imagiacanexia.com.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
May 15, 2023
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.